Treos Bio Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Treos Bio Limited - overview
Established
2013
Location
London, -, UK
Primary Industry
Biotechnology
About
Treos Bio Limited is focused on pioneering peptide immunotherapies to improve cancer treatment, leveraging advanced peptide technology to enhance immune response against tumors. Treos Bio Limited, founded in 2013, is based in London, UK, and specializes in developing innovative immunotherapies for cancer. The company has completed 2 deals, with the most recent funding round occurring on March 31, 2021. In this round, Treos Bio raised USD 14.
00 mn in Venture Debt from investors including Future Fund and Luminous Ventures. The total amount raised by the company to date is USD 8. 04 mn. John Hautman is the founder of Treos Bio, who has previous entrepreneurial experience in the biotechnology sector.
Treos Bio specializes in innovative off-the-shelf peptide immunotherapies, utilizing advanced peptide technology known as Promiscuous Epitope (PEPI). The flagship product, PolyPEPI1018, is a multi-peptide immunotherapy designed specifically for colorectal cancer, featuring proprietary peptides that stimulate immune responses against tumor antigens. With a focus on scalability, the peptides can be produced without the need for tumor biopsies, enhancing accessibility for varied patient demographics across global markets with a high incidence of colorectal cancer. In the most recent fiscal year of 2023, Treos Bio reported zero revenue, with an EBITDA of USD -4,447,112.
The company generates revenue primarily through its PolyPEPI immunotherapy products, partnering with healthcare providers and institutions for distribution to hospitals and clinics offering cancer treatments. Following the March 31, 2021 deal, Treos Bio, Limited intends to utilize the USD 14. 00 mn in funding to advance the clinical development of its novel cancer immunotherapy technology. This includes applying proprietary data science to match antigens expressed by specific cancers to individual patient genetics, which is aimed at enhancing treatment outcomes.
The company is also exploring opportunities to expand into new markets with higher colorectal cancer prevalence, although specific regions and timelines for these expansions have not been disclosed.
Current Investors
BXR Group, Future Fund, Luminous Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Epidemiology, Oncology/Cancer Treatment
Website
www.treosbio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Treos Bio Limited - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | 250,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (1,158,799) | (771,717) | (4,195,619) | (6,398,112) | (4,888,485) | - | - | - |
| Operating Income (USD) | (1,158,799) | (771,717) | (4,247,128) | (6,431,021) | (4,909,675) | - | - | - |
| Operating Margin | - | - | - | - | (1963.9%) | - | - | - |
| % EBITDA Margin | - | - | - | - | (1955.4%) | - | - | - |
| NET Income (USD) | (2,298,569) | (2,067,717) | (4,708,717) | (6,503,369) | (5,286,724) | - | - | - |
| % Net Margin | - | - | - | - | (2114.7%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.